You are here

Articles

Blocking rogue gene could stop the spread of most cancers

Posted on Tuesday, January 25, 2011 - 11:45am
Published: 24/01/2011 12:27:29 Scientists at the University of East Anglia have discovered a rogue gene which – if blocked by the right drugs – could stop cancer in its tracks.Published today by the journal ...
Read more

BELA Trial: Similar Rate of CCyR With Bosutinib vs Imatinib in Newly Diagnosed Patients With Ph-Positive CML-CP

Posted on Sunday, January 16, 2011 - 6:35pm
BELA Trial: Similar Rate of CCyR With Bosutinib vs Imatinib in Newly Diagnosed Patients With Ph-Positive CML-CP Posting Date: December 11, 2010 BELA: international, multicenter, randomized, open-...
Read more

Seeking the causes of and solutions to imatinib resistance in CML

Posted on Sunday, January 16, 2011 - 5:35pm
Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia D Bixby and M Talpaz Division of Hematology and Oncology, Department of Internal Medicine...
Read more

First-line dasatinib, nilotinib sustain their edge over imatinib

Posted on Sunday, January 16, 2011 - 5:31pm
First-Line Dasatinib, Nilotinib Sustain Edge Over Imatinib Elsevier Global Medical News. 2010 Dec 21,
Read more

ASH 2010 - pick of abstracts

Posted on Wednesday, December 1, 2010 - 1:05pm
  Novel CML Drug Active After Failures of Imatinib, Dasatinib, and Nilotinib Elsevier Global Medical News. 2010 Dec 6, JS MacNeil
Read more

Oncologystat- CML The Changing Landscape: Interview with Prof. Apperley-Parts 1 and 2

Posted on Thursday, November 25, 2010 - 12:30pm
  CML—The Changing Landscape of Front-line Therapy: Part I: Interview With Dr. Jane Apperley
Read more

ASH 2010 - Orlando

Posted on Tuesday, November 9, 2010 - 12:13pm
Chronic Myeloid Leukemia: An Historical Perspective Michael W. Deininger
Read more

Nature News- Cellular 'alchemy' transforms skin into blood 7/11/2010

Posted on Tuesday, November 9, 2010 - 12:04pm
  Published online 7 November 2010 | Nature | doi:10.1038/news.2010.588
Read more

Advances in the Treatment and Management of Patients With CML: A Nurse's Perspective CE Patricia S. Ault, MSN, RN

Posted on Thursday, October 21, 2010 - 12:54pm
Editor's Note:  Chronic myeloid leukemia (CML) represents approximately 11% of all adult forms of leukemia, and in 2009, approximately 5050 cases were diagnosed in the United...
Read more

Second-Generation BCR-ABL Kinase Inhibitors in CML

Posted on Thursday, October 21, 2010 - 12:07pm
CORRESPONDENCE  Second-Generation BCR-ABL Kinase Inhibitors in CML; N Engl J Med 2010; 363:1672-1675October 21, 2010
Read more

CHMP positive recommendation for use of Tasigna in Newly Diagnosed Ph+ CML

Posted on Saturday, September 25, 2010 - 12:01pm
http://www.ema.europa....
Read more

Changing the Culture of Clinical Trials: Reviving a Failing Effort

Posted on Wednesday, September 22, 2010 - 7:56pm
Changing the Culture of Clinical Trials: Reviving a Failing Effort 2010 Sept 22, Lee Schwartzberg, MD, FACP, Editor-in-Chief Cancer research is in big trouble. Surprised? Take issue with this statement? Yes,...
Read more

NEJM article: “Liberating the NHS” — Another Attempt to Implement Market Forces in English Health Care

Posted on Wednesday, September 22, 2010 - 12:07pm
  Nick Black, M.D.- N Engl J Med 2010; 363:1103-1105September 16, 2010
Read more

New BCR/Abl Inhibitor from Ariad Pharmaceuticals

Posted on Tuesday, September 21, 2010 - 11:26am
Ponatinib (AP24534) Pivotal Trial in Drug-Resistant or Intolerant Chronic Myeloid Leukemia Ariad's new drug for CML is now in clinical trial and has Orphan drug status from FDA and EMA. ...
Read more

Blood Journal-Long-term prognostic significance of early molecular response to imatinib

Posted on Wednesday, August 25, 2010 - 7:45pm
Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the international randomized study of interferon versus STI571 (IRIS). an...
Read more